American Society of Hematology

Figure 5

$Figure 5. Accelerating FXa-initiated clotting requires even shorter polyP polymers in the presence of added TFPI. Clotting reactions were conducted as in Figure 4A, except that plasma contained 400 ng/mL TFPI, clotting was initiated with 0.1nM FXa and polyP, when included, was at 20μM. Percent TFPI inhibition was calculated by comparing polyP clot times to a standard curve in the absence of polyP, but in which 0-400 ng/mL TFPI had been added to plasma (not shown). Sized-fractionated polyP preparations (▾) are compared with platelet-derived polyP (“Platelet,” at 150μM), bacterial-derived polyP (“Bact”), and polyP type 65. The inset focuses on polymers shorter than 200mers. Data are mean ± SE (n = 3).$

Accelerating FXa-initiated clotting requires even shorter polyP polymers in the presence of added TFPI. Clotting reactions were conducted as in Figure 4A, except that plasma contained 400 ng/mL TFPI, clotting was initiated with 0.1nM FXa and polyP, when included, was at 20μM. Percent TFPI inhibition was calculated by comparing polyP clot times to a standard curve in the absence of polyP, but in which 0-400 ng/mL TFPI had been added to plasma (not shown). Sized-fractionated polyP preparations (▾) are compared with platelet-derived polyP (“Platelet,” at 150μM), bacterial-derived polyP (“Bact”), and polyP type 65. The inset focuses on polymers shorter than 200mers. Data are mean ± SE (n = 3).

This Feature Is Available To Subscribers Only